Verona Pharma COPD Treatment 2022 Investor Presentation

Verona Pharma presented Phase 3 clinical data for ensifentrine, a first-in-class dual PDE3/PDE4 inhibitor for COPD maintenance treatment, addressing a market of over $10 billion with significant unmet need. The presentation highlights positive Phase 3 efficacy results on lung function and exacerbations, with safety consistent with placebo, and identifies pulmonologists and Medicare Part B as key commercial channels.